MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma.[1][2][3][4]

See also

References

  1. ^ Mukai, Yuki; Lupinacci, Robert; Marder, Stephen; Mackle, Mary; Snow-Adami, Linda; Voss, Tiffini; Smith, Sean; Egan, Michael (May 2022). "P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia". Biological Psychiatry. 91 (9): S305. doi:10.1016/j.biopsych.2022.02.771. S2CID 248410630.
  2. ^ Smith, Sean; Uslaner, Jason; Kandebo, Monika; Hostetler, Eric; Raheem, Izzat; Layton, Mark; Gantert, Liza; Riffel, Kerry; Cox, Christopher; Khalilieh, Sauzanne; De Lepeleire, Inge; Bormans, Guy; Depré, Marleen; de Hoon, Jan; Van Laere, Koen (May 2022). "P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor". Biological Psychiatry. 91 (9): S309 – S310. doi:10.1016/j.biopsych.2022.02.783. S2CID 248410556.
  3. ^ Layton, Mark E.; Kern, Jeffrey C.; Hartingh, Timothy J.; Shipe, William D.; Raheem, Izzat; Kandebo, Monika; Hayes, Robert P.; Huszar, Sarah; Eddins, Donnie; Ma, Bennett; Fuerst, Joy; Wollenberg, Gordon K.; Li, Jing; Fritzen, Jeff; McGaughey, Georgia B.; Uslaner, Jason M.; Smith, Sean M.; Coleman, Paul J.; Cox, Christopher D. (26 January 2023). "Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia". Journal of Medicinal Chemistry. 66 (2): 1157–1171. doi:10.1021/acs.jmedchem.2c01521. PMC 9884086. PMID 36624931. S2CID 255567942.
  4. ^ "MK-8189: A Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia". Synfacts. 19 (4): 0410. April 2023. doi:10.1055/s-0042-1752651. S2CID 257614478.
Allikas: https://en.wikipedia.org/wiki/MK-8189
No tags for this post.